Pfizer Ventures and Penn Medicine both contributed to an oversubscribed series A round for University of Pennslyvania spinout Interius Biotherapeutics.

US-based gene therapy developer Interius Biotherapeutics pocketed $76m in a series A round backed by pharmaceutical firm Pfizer and academic medical centre Penn Medicine today.

Cormorant Asset Management and Fairmount Funds co-led the round, which also attracted University of Pennsylvania (UPenn), Osage University Partners, Bain Capital Life Sciences, RA Capital Management, Longwood Fund, Logos Capital and Quan Capital.

Tellus Bioventures, Agent Capital, Mark Foundation for Cancer Research, Knollwood and American Cancer Society’s impact investment fund BrightEdge filled out the round.…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn